Skip to content
value.today

Kezar Life Sciences, Inc.

Total raised
$78 M
2 rounds on record
Latest round
$50 M
Jun 2017
First round on record
Jun 2015
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Kezar Life Sciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2017$50 MNo. 2$50 to $250 million

Kezar Life Sciences, Inc.: Raise no. 2, Jun 2017

Investors in this round

24 investors had bought by the notice of Aug 3, 2017: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 19 investors are named for Kezar Life Sciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher J Kirk · Executive Officer, Director
  • John F Fowler · Executive Officer, Director
  • Bihua J Chen · Director
  • Franklin J Berger · Director
  • Gerald J Chan · Director
  • Jean-Pierre J Sommadossi · Director
  • Michael J Kauffman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Christopher Kirk, President. Source: SEC Form D, newest notice filed Aug 3, 2017. Read the notice at the SEC.

equitySEC
Jun 2015$28 MNo. 1$10 to $50 million

Kezar Life Sciences, Inc.: Raise no. 1, Jun 2015

Investors in this round

49 investors had bought by the notice of Jun 22, 2015: 49 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 19 investors are named for Kezar Life Sciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$28 M of $28 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher J. Kirk · Executive Officer, Director
  • John F. Fowler · Executive Officer, Director
  • Dr. Gerald J. Chan · Director
  • Dr. Jean-Pierre J. Sommadossi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John F. Fowler, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 22, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Kezar Life Sciences, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2017).

    SEC Form D · Aug 2017

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2017

That is all the official record says: Kezar Life Sciences, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

19 named in official filings. Open an investor to see everything it has backed.

Investors in Kezar Life Sciences, Inc.
InvestorKindAmountRoundRoleSource
Aberdare Management Company, LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Amgen IncCompanynot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2018)SEC Form 3
AMP&A Management V, LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
A.M. Pappas & Associates, LLCOthernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
A.M. Pappas Life Science Ventures V, LPVenture capitalnot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Bay City Capital LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Chiesi Ventures, Inc.Venture capitalnot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Chiesi Ventures, LPVenture capitalnot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Cormorant Asset Management, LPFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Cormorant Global Healthcare Master Fund, LPFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Cormorant Private Healthcare Fund I, LPFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Franklin M. BergerPersonnot statednot statedHeld Series A and B preferred stock, director (Form 3, 2018)SEC Form 3
Michael KauffmanPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2018)SEC Form 3
Morningside Venture Investments LtdVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Omega Fund IV GP, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Omega Fund IV G.P. Manager, Ltd.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Omega Fund IV, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Onyx Therapeutics, Inc.Companynot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2018)SEC Form 3
PV V CEO Fund, LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2018)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 49 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Kezar Life Sciences, Inc.
NameRoleNamed in
Christopher J KirkExecutive officerAug 2017
John F FowlerExecutive officerAug 2017
Christopher J. KirkExecutive officerJun 2015
John F. FowlerExecutive officerJun 2015
Bihua J ChenDirectorAug 2017
Christopher J KirkDirectorAug 2017
Franklin J BergerDirectorAug 2017
Gerald J ChanDirectorAug 2017
Jean-Pierre J SommadossiDirectorAug 2017
John F FowlerDirectorAug 2017
Michael J KauffmanDirectorAug 2017
Christopher J. KirkDirectorJun 2015
Dr. Gerald J. ChanDirectorJun 2015
Dr. Jean-Pierre J. SommadossiDirectorJun 2015
John F. FowlerDirectorJun 2015